Literature DB >> 28066650

Whole brain radiotherapy for brain metastases from non-small cell lung cancer: the end of an era?

Anna M E Bruynzeel1, Frank J Lagerwaard1.   

Abstract

Entities:  

Year:  2016        PMID： 28066650      PMCID： PMC5179392          DOI： 10.21037/jtd.2016.11.41

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

1.  Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma.

Authors:  A Law; D D Karp; T Dipetrillo; B T Daly
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

2.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.

Authors:  B Borgelt; R Gelber; S Kramer; L W Brady; C H Chang; L W Davis; C A Perez; F R Hendrickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-01       Impact factor: 7.038

Review 4.  Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer.

Authors:  Nam Bui; Brian Woodward; Anna Johnson; Hatim Husain
Journal:  Curr Treat Options Oncol       Date:  2016-05

5.  Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases.

Authors:  L E Gaspar; C Scott; K Murray; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-01       Impact factor: 7.038

6.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Authors:  Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher
Journal:  JAMA       Date:  2016-07-26       Impact factor: 56.272

8.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.

Authors:  Masaaki Yamamoto; Toru Serizawa; Takashi Shuto; Atsuya Akabane; Yoshinori Higuchi; Jun Kawagishi; Kazuhiro Yamanaka; Yasunori Sato; Hidefumi Jokura; Shoji Yomo; Osamu Nagano; Hiroyuki Kenai; Akihito Moriki; Satoshi Suzuki; Yoshihisa Kida; Yoshiyasu Iwai; Motohiro Hayashi; Hiroaki Onishi; Masazumi Gondo; Mitsuya Sato; Tomohide Akimitsu; Kenji Kubo; Yasuhiro Kikuchi; Toru Shibasaki; Tomoaki Goto; Masami Takanashi; Yoshimasa Mori; Kintomo Takakura; Naokatsu Saeki; Etsuo Kunieda; Hidefumi Aoyama; Suketaka Momoshima; Kazuhiro Tsuchiya
Journal:  Lancet Oncol       Date:  2014-03-10       Impact factor: 41.316

9.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Authors:  Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley
Journal:  Lancet       Date:  2016-09-04       Impact factor: 79.321
  9 in total
  2 in total

1.  Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer.

Authors:  Ahmed Mohieldin; Ayman Rasmy; Mohamed Ashour; Muath Al-Nassar; Rola H Ali; Fahad G El-Enezi
Journal:  Cancer Manag Res       Date:  2018-11-29       Impact factor: 3.989

Review 2.  Management of brain metastases in elderly patients with lung cancer.

Authors:  Joanna Socha; Anna Rychter; Lucyna Kepka
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 3.005
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.